Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Twist Bioscience (TWST) to $44 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cautious Outlook on Twist Bioscience Amidst Macroeconomic Challenges and Premium Valuation
- Twist Bioscience price target lowered to $33 from $40 at JPMorgan
- Twist Bioscience Reports Record Revenue and Strategic Spin-Out
- Twist Bioscience’s Earnings Call Highlights Record Growth
- Morning Movers: Skechers surges following take-private deal